Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Kiniksa Pharmaceuticals International PLC KNSA

Healthcare Biotechnology
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a... see more

Current News (NDAQ:KNSA)

Kiniksa Pharmaceuticals Provides Corporate Update

GlobeNewswire January 12, 2026

Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2026

Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

GlobeNewswire November 12, 2025

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

GlobeNewswire October 28, 2025

Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025

GlobeNewswire October 23, 2025

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis

GlobeNewswire October 17, 2025

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire August 28, 2025

Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

GlobeNewswire July 29, 2025

Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025

GlobeNewswire July 24, 2025
View More News ››

Opinion & Analysis (NDAQ:KNSA)

Kiniksa Shares Trade Up 30% on COVID-19 Pneumonia and Hyperinflammation Treatment

Streetwise Reports April 1, 2020

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug

Streetwise Reports November 21, 2019
View More Opinion ››

Bullboard Posts (NDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd. (KNSA): A Promising Biopharmac

http://beyondspx.com/2024/07/31/kiniksa-pharmaceuticals-ltd-knsa-a-promising-biopharmaceutical-company-driving-growth-through...
MikeTester - August 2, 2024
View more Bullboard ››

LaFleur Minerals Inc.

LaFleur Minerals Inc.

LaFleur Minerals Inc. explores for lithium and gold deposits in Canada. The company holds interest in the Swanson Gold ...
View More »

Podcasts